New cutaneous toxicities with generic docetaxel: are the excipients guilty?

Supportive Care in Cancer

Volumn 23, Issue 7, 2015, Pages 1917-1923

  Garrido Siles, Margarita ^a   Arenas Villafranca, Jose Javier ^a   Pérez Ruiz, Elísabeth ^a   de Linares Fernández, M Francisca ^a   Tortajada, Begoña ^a   Rivas Ruiz, Francisco ^a   Faus, Vicente ^a   Rueda, Antonio ^a  

^a HOSPITAL COSTA DEL SOL   (Spain)

Author keywords

Cancer; Docetaxel; Excipients; Toxicity

Indexed keywords

ALCOHOL; CISPLATIN; CITRIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DEXCHLORPHENIRAMINE; DOCETAXEL; DOXORUBICIN; EXCIPIENT; FLUOROURACIL; POLYSORBATE 80; TRASTUZUMAB; ANTINEOPLASTIC AGENT; GENERIC DRUG; TAXOID;

ADULT; ARTICLE; BACKACHE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CONTROLLED STUDY; DIZZINESS; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ESOPHAGUS CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; LONGITUDINAL STUDY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PATIENT HISTORY OF CHEMOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK FACTOR; SKIN TOXICITY; STOMACH CANCER; TACHYCARDIA; AGED; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; SKIN; SKIN DISEASE;

AGED; ANTINEOPLASTIC AGENTS; DRUGS, GENERIC; EXCIPIENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN; SKIN DISEASES; TAXOIDS;

EID: 84929950406     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2499-2     Document Type: Article

References (21)

1. Bissery MC, Nohynek G, Sanderink GJ et al (1995) Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 6:339–355
2. Food and Drug Administration (2012) Approved drug products with therapeutic equivalence evaluations (Orange Book). (32nd ed). Washington, DC: US Department of Health and Human Services; pp vi-viii
3. Generic Pharmaceutical Association (2009) Economic analysis of generic pharmaceuticals 1999–2008: $734 billion in health care savings. Arlington, VA. Publishing in http://multivu.prnewswire.com/mnr/GPhA/38110/docs/38110-734_Billion_in_Generic_Savings_GPhA.pdf. Accessed 15 May 2014
4. Tije AJ, Verweij J, Loos WJ et al (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42(7):665–685
5. Drori S, Eytan GD, Assaraf YG (1995) Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 228:1020–1029
6. Mark M, Walter R, Meredith DO et al (2001) Commercial taxane formulations induce stomatocytosis and increase blood viscosity. Br J Pharmacol 134:1207–1214
7. Zuccotti GV, Fabiano V (2011) Safety issues with ethanol as an excipient in drugs intended for pediatric use. Expert Opin Drug Saf 10(4):499–502. doi:10.1517/14740338.2011
8. Taxotere®. European Medicines Agency. Publishing in http://ema.europa.eu/docs/es_ES/document_library/EPAR_Product_Information/human/000073/WC500035264.pdf. Accessed 10 March 2014
9. Van Zuylen L, Verweij J, Sparreboom A (2001) Role of formulation vehicles in taxane pharmacology. Investig New Drugs 19:125–141
10. Weiszhar Z, Czucz J, Revesz C et al (2012) Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci 45:492–498
11. Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Publised:May 28, 2009. U.S. Departament of Health and Human Services
12. Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13:2634–2655
13. Lee C, Gianos M, Klaustermeyer WB (2009) Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Inmunol 102:179–187
14. Schrijves D, Wanders J, Dirix L et al (1993) Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4:610–611
15. Ardavanis A, Tryfonopoulos D, Yiotis I et al (2004) (2004). Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 15:581–585
16. Vial J, Cohen M, Sassiat P et al (2008) Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis. Curr Med Res Opin 24:2019–2033
17. CheW L, Chuen VS (2009) Cutaneous reactions associated with weekly docetaxel administration. J Oncol Pharm Pract 15:29–34
18. Polovich M, Whitford J, Olsen M (2009) Chemotherapy and biotherapy guidelines and recommendation for practice, 3rd edn. Oncology Nursing Society, Pittsburgh
19. Sanofi-aventis USLLC (2011) Taxotere® prescribing information. Sanofi-aventis US LLC., Bridgewater
20. Barbee M, Owonikoko TK, Harvey RD (2014) Taxanes: vesicants, irritants or just irritating. Ther Adv Med Oncol 6:16–20
21. Poirier E, Desbiens C, Poirier B et al (2013) Comparations of serious adverse events between the original and a generic docetaxel in breast cancer patients. Ann Pharmacother. doi:10.1177/1060028013514941